Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445650 · ClinicalTrials.gov registry record · Phase 3
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
A Phase 3 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT03445650 is a Phase 3 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 11 participants.
The verdict
NCT03445650, a Phase 3 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).
Interventions
- DRUG ADX-102 1% Topical Dermal Cream (reproxalap)
- DRUG Vehicle of ADX-102 Topical Dermal Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2020-01-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03445650
The ClinicalTrials.gov registry entry for NCT03445650 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADX-102 1% Topical Dermal Cream (reproxalap) is the first listed.
NCT03445650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03445650 about?
NCT03445650 is a clinical study titled "RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)". A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).
What is the current status of trial NCT03445650?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2018-07-18. Estimated completion is 2020-01-18.
What interventions are being tested in trial NCT03445650?
The interventions under investigation include: ADX-102 1% Topical Dermal Cream (reproxalap) (DRUG), Vehicle of ADX-102 Topical Dermal Cream (DRUG).
Who is sponsoring clinical trial NCT03445650?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.